Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: Recent case study of oral atorvastatin and verapamil

European Journal of Clinical Pharmacology

Volumn 64, Issue 11, 2008, Pages 1135-1136

  Srinivas, Nuggehally R ^a  

^a ClinTec India International Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATORVASTATIN; CYTOCHROME P450 3A4; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; VERAPAMIL;

DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG EFFICACY; HUMAN; LETTER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; STEADY STATE;

CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; P-GLYCOPROTEIN; PYRROLES; VERAPAMIL;

EID: 55349099134     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0512-8     Document Type: Letter

References (21)

1. DH Choi WG Shin JS Choi 2008 Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil Eur J Clin Pharmacol 64 445 449
2. AS Etheridge SR Black PR Patel J So JM Mathews 2007 An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents Plant Med 73 731 741
3. SW Grimm NM Richtand HR Winter KR Stams SB Reels 2006 Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics Br J Clin Pharmacol 61 58 69
4. PJ Neuvonen M Niemi JT Backman 2006 Drug interactions with lipid lowering drugs: mechanisms and clinical relevance Clin Pharmacol Ther 80 565 581
5. MK Ma HL McLeod 2003 Lessons learnt from the irinotecan metabolic pathway Curr Med Chem 10 41 49
6. WP Lemahieu M Hermann A Asberg K Verbeke H Holdaas Y Vanrenterghem BD Maes 2005 Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus Am J Transplant 5 2236 2243
7. LZ Benet CL Cummins CY Wu 2004 Unmasking the dynamic interplay between efflux transporters and metabolic enzymes Int J Pharm 277 3 9
8. LZ Benet CL Cummins CY Wu 2003 Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data Curr Drug Metab 4 393 398
9. CL Cummins W Jacobsen CY Wu 2002 Unmasking the dynamic interplay between intestinal P-gycoprotein and CYP3A4 J Pharmacol Exp Ther 300 1036 1045
10. J Prakash T Velpandian JN Pande SK Gupta 2003 Serum rifampicin levels in patients with tuberculosis: effect of P-gycoprotein and CYP3A4 blockers on its absorption Clin Drug Investig 23 463 472
11. CW Holtzman BS Higgins SA Spinler 2006 Role of P-glycoprotein in statin drug interactions Pharmacotherapy 26 1601 1607
12. CG McDonnell G Shorten FN Van Pelt 2005 Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro Anaesthesia 60 747 753
13. WP Lemahieu BD Maes K Verbeke Y Vanrenterghem 2005 Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation Kidney Int 67 1152 1160
14. LZ Benet CL Cummins 2001 The drug efflux-metabolism alliance: biochemical aspects Adv Drug Deliv Rev 50 S3 S11
15. JH Hochman M Chiba J Nishima M Yamazaki JH Lin 2000 Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P450 3A4 J Pharmacol Exp Ther 292 310 318
16. JM Custodio CY Wu LZ Benet 2008 Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption Adv Drug Deliv Rev 60 717 733
17. J Popovic 2007 Validation of the hepatic blood flow rate model for verapamil first-pass metabolism Eur J Drug Metab Pharmacokinet 32 13 19
18. Y Shitara Y Sugiyama 2006 Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions Pharmacol Ther 112 71 105
19. M Kato K Chiba A Hisaka M Ishigami M Kayama N Mizuno 2003 The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature Drug Metab Pharmacokinet 18 365 372
20. T Kantola KT Kivisto PJ Neuvonen 1998 Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations Clin Pharmacol Ther 64 177 182
21. ES Perloff SX Duan PR Skolnik DJ Greenblatt LL von Moltke 2005 Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro Drug Metab Dispos 33 764 770